Examples of using Applicant data in English and their translations into Bulgarian
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Statement of applicant data in an orderly fashion;
However, you can delete your profile and your personal applicant data at any time.
Update for EU applicant data by nation.
The applicant data is made anonymous in Australia after 2 years.
Upon receipt of your application, your applicant data will be reviewed by the Human Resources Department.
People also translate
The applicant data is made anonymous in Australia after 2 years.
In all other cases, the legal basis for storing your applicant data is your consent pursuant to Art. 6(1)(a) GDPR.
Applicant data- name, personal identity number, permanent address- for natural persons;
In the case of rejection, applicant data will be deleted after six months.
Applicant data- name, personal identity number, permanent address- for natural persons; certificate reflecting current status of entry in the Commercial Register;".
The deletion of the profile occurs instantly while the anonymisation of the personal applicant data is carried out in accordance with the above statutory deletion period.
Your applicant data will be screened by the human resources department after your application is received.
Should you be awarded the position during the application process,the data from the applicant data system are transferred to our personnel information system.
Your personal applicant data is only passed on to employees who co-determine who will fill the position.
This dataset records planning applications where a financial contribution towards the infrastructure oraffordable housing has been secured from the applicant data. gov. uk| January 7, 2017 XML.
The processing of your applicant data is necessary in order to be able to decide on the employment justification.
Should you have been awarded the contract as part of the application process,the data from the applicant data system will be transferred to our personnel information system.
Your personal applicant data will not be passed on to third parties or persons who are not involved in the decision-making process.
In the event that your application to work at or for Cochlear is successful,we will retain your job applicant data for the duration of your employment/engagement at Cochlear.
Applicant data is held for up to six months after the application process is complete before being deleted, unless you provide your express consent for us to keep your applicant data on file for up to two years.
If you leave Cochlear's employment/engagement, your job applicant data will be deleted in accordance with Cochlear's internal data retention and deletion standards.
Cochlear deletes job applicant data within 12 months of an unsuccessful application, unless you have asked Cochlear to keep the application data on file to consider you for future roles, in which case the data will be deleted within 5 years of the last time you were considered for a role.
Since 2009, the Commission has further developed the Potential Applicant Data Online Registration(PADOR) database containing potential applicants to calls for proposals.
This increases the possibility of foreseeing our actions both for the Commission internal use of resources as well as for the NSAs in order to plan their strategy and investments for the submission.(c)PADOR(Potential Applicant Data Online Registration) simplifies and decreases the selection time process.(d) Indeed, the possibility of adapting calls for proposals increases the efficiency of the process in selecting relevant NSAs, as demonstrated by the first experiences in local calls for proposals.
The applicant presented data on experimental models from similar vaccines.
The applicant presented data on experimental models from the scientific literature.
The applicant presented data from one main study involving 202 patients with PAH.
The applicant presented data on experimental models from the scientific literature.
The applicant presented data on an existing nebuliser solution containing tobramycin called Tobi.
The applicant presented data from two main studies in 356 anaemic patients with myelodysplastic syndromes.